CIK 2102314
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2025-Q4. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Pharmaceuticals & Biotechnology | 93.10% | 24 |
| Unclassified | 6.90% | 2 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | BMRN | BIOMARIN PHARMACEUTICAL INC | Health Care | 15.36% |
| 2 | VRTX | VERTEX PHARMACEUTICALS INC / MA | Health Care | 10.40% |
| 3 | PCVX | Vaxcyte, Inc. | Health Care | 8.03% |
| 4 | NUVL | Nuvalent, Inc. | Health Care | 6.61% |
| 5 | CAPR | CAPRICOR THERAPEUTICS, INC. | Health Care | 5.93% |
| 6 | TERNS PHARMACEUTICALS INC | Unclassified | 5.89% | |
| 7 | BCAX | Bicara Therapeutics Inc. | Health Care | 5.37% |
| 8 | ANIP | ANI PHARMACEUTICALS INC | Health Care | 5.25% |
| 9 | RARE | Ultragenyx Pharmaceutical Inc. | Health Care | 5.23% |
| 10 | ELVN | Enliven Therapeutics, Inc. | Health Care | 4.98% |
24/26 names classified · sector 93.1% of weight · industry 93.1% · mkt cap 89.0%; unclassified names shown, never dropped.
Only 31% of book weight classified — the grid is NOT representative of the whole book.
Classified: 31.0% of book weight (3/26 names) · unclassified 69.0%: PCVX, NUVL, CAPR, , BCAX, RARE, ELVN, AMLX, ARGX, FULC +13 more. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| # | Security | Shares | Value | Weight | Δ QoQ |
|---|---|---|---|---|---|
| 1 | BMRNBIOMARIN PHARMACEUTICAL INC | 1,268,390 | $72M | 15.4% | NEW |
| 2 | VRTXVERTEX PHARMACEUTICALS INC | 108,603 | $48M | 10.4% | NEW |
| 3 | PCVXVAXCYTE INC | 644,831 | $37M | 8.0% | NEW |
| 4 | NUVLNUVALENT INC | 300,830 | $31M | 6.6% | NEW |
| 5 | CAPRCAPRICOR THERAPEUTICS INC | 909,207 | $28M | 5.9% | NEW |
| 6 | TERNS PHARMACEUTICALS INC | 521,237 | $27M | 5.9% | NEW |
| 7 | BCAXBICARA THERAPEUTICS INC | 1,260,136 | $25M | 5.4% | NEW |
| 8 | ANIPANI PHARMACEUTICALS INC | 318,591 | $24M | 5.3% | NEW |
| 9 | RAREULTRAGENYX PHARMACEUTICAL IN | 1,165,557 | $24M | 5.2% | NEW |
| 10 | ELVNENLIVEN THERAPEUTICS INC | 593,040 | $23M | 5.0% | NEW |
| 11 | AMLXAMYLYX PHARMACEUTICALS INC | 1,598,794 | $22M | 4.8% | NEW |
| 12 | ARGXARGENX SE | 25,995 | $19M | 4.1% | NEW |
| 13 | FULCFULCRUM THERAPEUTICS INC | 1,771,926 | $14M | 2.9% | NEW |
| 14 | VIRVIR BIOTECHNOLOGY INC | 1,198,213 | $11M | 2.3% | NEW |
| 15 | NUVBNUVATION BIO INC | 2,383,031 | $10M | 2.2% | NEW |
| 16 | ORKAORUKA THERAPEUTICS INC | 140,843 | $7M | 1.5% | NEW |
| 17 | CTNMCONTINEUM THERAPEUTICS INC | 513,053 | $7M | 1.4% | NEW |
| 18 | MANEVeradermics Inc | 100,843 | $6M | 1.4% | NEW |
| 19 | TNXPTONIX PHARMACEUTICALS HLDG C | 452,116 | $6M | 1.3% | NEW |
| 20 | GPCRSTRUCTURE THERAPEUTICS INC | 100,593 | $5M | 1.0% | NEW |
| 21 | TRDAENTRADA THERAPEUTICS INC | 374,010 | $5M | 1.0% | NEW |
| 22 | PHVSPHARVARIS N V | 167,014 | $5M | 1.0% | NEW |
| 23 | TRVITREVI THERAPEUTICS INC | 370,175 | $4M | 0.9% | NEW |
| 24 | RLMDRELMADA THERAPEUTICS INC | 342,752 | $2M | 0.5% | NEW |
| 25 | SLNSILENCE THERAPEUTICS PLC | 301,604 | $2M | 0.3% | NEW |
| 26 | AVBPARRIVENT BIOPHARMA INC | 45,809 | $1M | 0.2% | NEW |
| Security | 2024-Q4 | 2025-Q1 | 2025-Q2 | 2025-Q3 | 2025-Q4 | 2026-Q1 | Latest value |
|---|---|---|---|---|---|---|---|
| BMRNBIOMARIN PHARMACEUTICAL INC | — | — | — | — | — | 1.3M | $72M |
| VRTXVERTEX PHARMACEUTICALS INC | — | — | — | — | — | 109K | $48M |
| PCVXVAXCYTE INC | — | — | — | — | — | 645K | $37M |
| NUVLNUVALENT INC | — | — | — | — | — | 301K | $31M |
| CAPRCAPRICOR THERAPEUTICS INC | — | — | — | — | — | 909K | $28M |
| TERNS PHARMACEUTICALS INC | — | — | — | — | — | 521K | $27M |
| BCAXBICARA THERAPEUTICS INC | — | — | — | — | — | 1.3M | $25M |
| ANIPANI PHARMACEUTICALS INC | — | — | — | — | — | 319K | $24M |
| RAREULTRAGENYX PHARMACEUTICAL IN | — | — | — | — | — | 1.2M | $24M |
| ELVNENLIVEN THERAPEUTICS INC | — | — | — | — | — | 593K | $23M |
| AMLXAMYLYX PHARMACEUTICALS INC | — | — | — | — | — | 1.6M | $22M |
| ARGXARGENX SE | — | — | — | — | — | 26K | $19M |
| FULCFULCRUM THERAPEUTICS INC | — | — | — | — | — | 1.8M | $14M |
| VIRVIR BIOTECHNOLOGY INC | — | — | — | — | — | 1.2M | $11M |
| NUVBNUVATION BIO INC | — | — | — | — | — | 2.4M | $10M |
Shares reported each quarter by the largest current holdings. Green = added vs the prior filing of that name, red = trimmed, grey = roughly held; a dash is a quarter with no 13F on file (a gap is skipped, not read as an exit). 13F is filed up to 45 days after quarter-end. Up to 40 quarters (10 years) available — use the selector above.
Where this firm's principals came from and which firms its alumni went on to found.
